Welcome to our dedicated page for CALCIMEDICA SEC filings (Ticker: CALC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
CalciMedica's SEC filings reveal the financial trajectory and operational decisions of a clinical-stage biopharmaceutical company advancing calcium channel inhibitors through human trials. The company's 10-Q quarterly reports detail cash burn rates, research and development expenditures, and runway projections that determine how long current capital can sustain operations before additional financing becomes necessary.
Form 4 filings track insider transactions, showing when executives and directors buy or sell shares. These transactions sometimes precede material announcements about clinical trial results or financing activities. CalciMedica's 8-K filings disclose material events including clinical trial updates, partnership agreements, and changes in capital structure. The prospectus supplements (424B5 forms) provide detailed terms of securities offerings, including share prices, dilution effects, and use of proceeds for specific research programs.
The company's annual 10-K filings offer comprehensive discussions of clinical trial designs, competitive landscape analysis, and risk factors specific to CRAC channel drug development. These documents explain the regulatory pathway for acute pancreatitis therapies and identify which biomarkers the company measures to demonstrate drug efficacy. Proxy statements reveal executive compensation structures and how management incentives align with clinical milestones.
Our AI-powered summaries extract key financial metrics from dense accounting disclosures, highlight changes in trial timelines buried in MD&A sections, and identify when insider buying patterns shift. No need to parse through 100+ pages of technical documentation to understand whether CalciMedica's cash position supports its stated development plans or when the next catalyst event might occur.
CalciMedica, Inc. disclosed that a group led by Avenue Venture Opportunities Fund II, L.P. beneficially owns 1,359,553 shares of common stock, representing 8.87% of the fully diluted class based on 13,972,177 shares. The reported holdings include 718,390 shares issuable upon conversion of a $2.0 million loan convertible at a per‑share price of $2.784 and 641,163 shares issuable upon exercise of outstanding warrants. Avenue Capital Management II, L.P. is the manager with sole voting and dispositive power over the Fund's shares but disclaims direct beneficial ownership except to the extent of pecuniary interest. The filing provides required ownership disclosure and related certifications.
CalciMedica insider activity: Eric W. Roberts, listed as Chief Business Officer, Director and a 10% owner, reported purchases of common stock on 08/28/2025 and 08/29/2025 totaling 10,000 shares acquired (9,200 at a weighted-average price of $2.863 and 800 at $2.74). The filing lists multiple indirect beneficial holdings across custodians and vehicles, including positions held by FMTC Custodian - Roth IRA, Oppenheimer & Co. Custodian, IRA Financial Trust Company, Valence Investments SPV IV/V/VI, and others, with several large indirect balances reported. The form also shows a disposition of 179,706 shares. The filer certified the report via attorney-in-fact signature on 09/02/2025.
CalciMedica insider transaction summary: Director and Chief Business Officer Eric W. Roberts reported transactions in CalciMedica (CALC) on 08/21/2025. The filing shows a purchase of 3,508 shares at a weighted average price of $2.7928 (price range $2.75–$2.80). The form also reports a disposition of 179,706 shares. After the reported purchase, Mr. Roberts beneficially owns multiple blocks of common stock across accounts and entities, including 60,907 shares held by an FMTC Custodian Roth IRA, 49,894 shares via Oppenheimer custodian Roth IRA, and additional holdings through Valence Investments SPV entities totaling hundreds of thousands of shares. The form was signed by an attorney-in-fact on 08/25/2025.
CalciMedica insider filing shows purchases and an option exercise increasing reported holdings. Eric W. Roberts reported purchases of 1,000 shares on 08/19/2025 at $2.79 and 2,000 shares on 08/20/2025 at $2.72. He also exercised an employee stock option for 15,000 shares at an exercise price of $1.53 on 08/20/2025.
The filing lists multiple custodial and indirect holdings across Roth IRA accounts and several Valence Investments SPVs, and shows 57,750 derivative securities reported as beneficially owned following the transactions.
CalciMedica insider purchase reported: The company's Chief Medical Officer, Sudarshan Hebbar, reported buying 9,563 shares of CalciMedica, Inc. (ticker: CALC) on 08/19/2025 at a weighted average purchase price of $2.8194, with individual trade prices ranging from $2.74 to $2.86. After the transaction, the reporting person beneficially owned 61,539 shares held directly. The Form 4 was signed by an attorney-in-fact on 08/21/2025 and discloses that breakdowns by price per lot are available upon SEC staff request.
Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported transactions on this Form 4 dated 08/15/2025. The filing shows an acquisition of 5,076 shares of Common Stock at a weighted-average purchase price of $2.8977 per share (price range $2.80 to $2.90). The form also reports a disposition of 164,706 shares and multiple indirect holdings held through custodians and affiliated entities including FMTC Custodian, Oppenheimer & Co. Custodian, IRA Financial Trust Company, and several Valence Investments SPVs. The filing includes a note that detailed per-price share counts are available upon request.
CalciMedica, Inc. (CALC) reporting person Hebbar Sudarshan, the company's Chief Medical Officer, purchased additional common stock in two transactions. On 08/14/2025 he acquired 1,584 shares at a weighted average price of $2.585, bringing his direct beneficial ownership to 47,584 shares. On 08/15/2025 he acquired 4,392 shares at a weighted average price of $2.793, increasing his direct ownership to 51,976 shares. The filing was signed by an attorney-in-fact on 08/18/2025. The filing includes price ranges for the trades and notes that detailed per-price purchase counts are available on request.
CalciMedica, Inc. filed a Form 8-K reporting that on August 12, 2025 it issued a press release announcing financial results for the fiscal quarter ended June 30, 2025. The press release is attached as Exhibit 99.1 and the filing also includes an Inline XBRL cover page as Exhibit 104. The company states the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and therefore is not subject to certain liabilities under the federal securities laws.
The report is signed by CEO A. Rachel Leheny, Ph.D.. The filing confirms the Nasdaq ticker CALC and that the registrant identified itself as an emerging growth company.
FAQ
What is the current stock price of CALCIMEDICA (CALC)?
What is the market cap of CALCIMEDICA (CALC)?
